These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 7742753

  • 1. In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood.
    Harris DT.
    Bone Marrow Transplant; 1995 Jan; 15(1):17-23. PubMed ID: 7742753
    [Abstract] [Full Text] [Related]

  • 2. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW, Shamim F, Hamon M, Macdonald ID, Prentice HG.
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [Abstract] [Full Text] [Related]

  • 3. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.
    Uharek L, Glass B, Gaska T, Zeiss M, Gassmann W, Löffler H, Müller-Ruchholtz W.
    Bone Marrow Transplant; 1993 Dec; 12 Suppl 3():S57-60. PubMed ID: 8124260
    [Abstract] [Full Text] [Related]

  • 4. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum.
    Webb BJ, Bochan MR, Montel A, Padilla LM, Brahmi Z.
    Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757
    [Abstract] [Full Text] [Related]

  • 5. Analysis of the alloreactive capacity of human umbilical cord blood: implications for graft-versus-host disease.
    Harris DT, LoCascio J, Besencon FJ.
    Bone Marrow Transplant; 1994 Oct; 14(4):545-53. PubMed ID: 7858529
    [Abstract] [Full Text] [Related]

  • 6. Cord blood transplantation: implications for graft vs. host disease and graft vs. leukemia.
    Harris DT.
    Blood Cells; 1994 Oct; 20(2-3):560-4; discussion 564-5. PubMed ID: 7749121
    [Abstract] [Full Text] [Related]

  • 7. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 8. Characterization of the alloreactivity and anti-leukemia reactivity of cord blood mononuclear cells.
    Keever CA, Abu-Hajir M, Graf W, McFadden P, Prichard P, O'Brien J, Flomenberg N.
    Bone Marrow Transplant; 1995 Mar 15; 15(3):407-19. PubMed ID: 7599566
    [Abstract] [Full Text] [Related]

  • 9. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ.
    J Clin Invest; 1998 May 01; 101(9):1835-42. PubMed ID: 9576746
    [Abstract] [Full Text] [Related]

  • 10. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA.
    Dan Med Bull; 2002 May 01; 49(2):89-108. PubMed ID: 12064093
    [Abstract] [Full Text] [Related]

  • 11. Effect of GVHD on the recovery of NK cell activity and LAK precursors following BMT.
    Keever CA, Klein J, Leong N, Copelan EA, Avalos BR, Kapoor N, Cunningham I, Tutschka PJ.
    Bone Marrow Transplant; 1993 Sep 01; 12(3):289-95. PubMed ID: 8241989
    [Abstract] [Full Text] [Related]

  • 12. Umbilical cord blood transplantation--how, when and for whom?
    Cohen Y, Nagler A.
    Blood Rev; 2004 Sep 01; 18(3):167-79. PubMed ID: 15183901
    [Abstract] [Full Text] [Related]

  • 13. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.
    Biol Blood Marrow Transplant; 1997 Apr 01; 3(1):11-7. PubMed ID: 9209736
    [Abstract] [Full Text] [Related]

  • 14. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G, Wu D, Wang Y, Cen J, Feng Y, Sun A, Tang X, Chang H, Zhu Z.
    Eur J Haematol; 2008 Sep 01; 81(3):226-35. PubMed ID: 18573173
    [Abstract] [Full Text] [Related]

  • 15. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L, Glass B, Zeis M, Dreger P, Steinmann J, Löffler H, Schmitz N.
    Exp Hematol; 1998 Feb 01; 26(2):93-9. PubMed ID: 9472798
    [Abstract] [Full Text] [Related]

  • 16. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
    Schönberger S, Niehues T, Meisel R, Bernbeck B, Laws HJ, Kögler G, Enzmann J, Wernet P, Göbel U, Dilloo D.
    Klin Padiatr; 2004 Feb 01; 216(6):356-63. PubMed ID: 15565551
    [Abstract] [Full Text] [Related]

  • 17. Graft-versus-leukemia effect in allogeneic bone marrow transplantation in mice against several radiation-induced leukemias.
    Aizawa S, Sado T, Kamisaku H, Nemoto K, Yoshida K.
    Bone Marrow Transplant; 1994 Feb 01; 13(2):109-14. PubMed ID: 8205078
    [Abstract] [Full Text] [Related]

  • 18. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S.
    Clin Transpl; 1996 Feb 01; ():281-90. PubMed ID: 9286578
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-2 in bone marrow transplantation: preclinical studies.
    Charak BS, Choudhary GD, Tefft M, Mazumder A.
    Bone Marrow Transplant; 1992 Aug 01; 10(2):103-11. PubMed ID: 1326364
    [Abstract] [Full Text] [Related]

  • 20. Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.
    Li JM, Giver CR, Waller EK.
    Exp Hematol; 2006 Jul 01; 34(7):895-904. PubMed ID: 16797417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.